{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:13:27Z","timestamp":1792242807409,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtho.2024.12.011","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T16:04:44Z","timestamp":1734365084000},"page":"437-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Aur\u00e9lie","family":"Swalduz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Schiffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bana","family":"Ambasager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Le Moel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Dot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Duruisseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fournel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Odier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Demolombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Acya","family":"Bizieux-Thaminy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Peytier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Hominal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bombaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Donnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ortiz-Cuaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitzan","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christodoulos","family":"Pipinikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Saintigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.12.011_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.011_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.011_bib3","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A\u00a0phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib4","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jtho.2022.01.012","article-title":"Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial","volume":"17","author":"Ahn","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/OP.20.00489","article-title":"Case of fatal immune-related skin toxicity from sequential use of Osimertinib after Pembrolizumab: lessons for drug sequencing in never-smoking non-small-cell lung cancer","volume":"16","author":"Cui","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtho.2024.12.011_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41416-020-01099-7","article-title":"A\u00a0Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced\/metastatic non-small-cell lung cancer","volume":"124","author":"Creelan","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2024.12.011_bib7","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib8","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lungcan.2014.08.016","article-title":"Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)","volume":"86","author":"Chouaid","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.12.011_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/thoraxjnl-2014-206677","article-title":"Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group","volume":"71","author":"Dietel","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jtho.2024.12.011_bib11","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.011_bib13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100399","article-title":"Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer","volume":"7","author":"Heitzer","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2024.12.011_bib15","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1158\/1078-0432.CCR-17-2588","article-title":"Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.011_bib16","article-title":"Clinical relevance of an amplicon-based liquid biopsy for detecting ALK and ROS1 fusion and resistance mutations in patients with non-small-cell lung cancer","volume":"4","author":"Mezquita","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.32503","article-title":"Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer","volume":"126","author":"Papadimitrakopoulou","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2024.12.011_bib18","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-19-1126","article-title":"Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.011_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cllc.2020.06.015","article-title":"Duration of targeted therapy in patients with advanced non-small-cell lung cancer identified by circulating tumor DNA analysis","volume":"21","author":"Reckamp","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.12.011_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00211","article-title":"Real-world utility of an amplicon-based next-generation sequencing liquid biopsy for broad molecular profiling in patients with advanced non-small-cell lung cancer","author":"Remon","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib21","article-title":"Plasma genotyping at the time of diagnostic tissue biopsy decreases time-to-treatment in patients with advanced NSCLC-results from a prospective pilot study","volume":"3","author":"Thompson","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2024.12.011_bib22","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2217\/fon-2018-0943","article-title":"Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients","volume":"15","author":"Swalduz","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194630","article-title":"Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA","volume":"13","author":"Gale","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.12.011_bib24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1078-0432.CCR-15-1627-T","article-title":"Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients","volume":"22","author":"Paweletz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.011_bib25","article-title":"Prospective clinical validation of the InVisionFirst-lung circulating tumor DNA assay for molecular profiling of patients with advanced nonsquamous non-small-cell lung cancer","volume":"3","author":"Pritchett","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2022.05.012","article-title":"Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients","volume":"171","author":"Cui","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2024.12.011_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2022.01.009","article-title":"A\u00a0pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer","volume":"165","author":"Cui","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.12.011_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.25332","article-title":"Association of circulating tumor DNA testing before tissue diagnosis with time to treatment among patients with suspected advanced lung cancer: the ACCELERATE nonrandomized clinical trial","volume":"6","author":"Garc\u00eda-Pardo","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2024.12.011_bib29","article-title":"Oncologist confidence in genomic testing and implications for using multimarker tumor panel tests in practice","volume":"4","author":"de Moor","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The International Association for the Study of Lung Cancer global survey on molecular testing in lung cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jnci\/djy156","article-title":"A\u00a0prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers","volume":"111","author":"Sabari","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2024.12.011_bib32","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.011_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtho.2018.10.008","article-title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer","volume":"14","author":"Schrock","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib34","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2020.38.15_suppl.1525","article-title":"Characterization of clonal hematopoiesis of indeterminate potential mutations from germline whole exome sequencing data","volume":"38","author":"Wu","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib35","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.011_bib36","article-title":"Liquid biopsy of lung cancer before pathological diagnosis is associated with shorter time to treatment","volume":"8","author":"Russo","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib37","article-title":"Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non-small-cell lung cancer","volume":"7","author":"Aggarwal","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib38","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/PO.21.00029","article-title":"Plasma cfDNA genotyping in hospitalized patients with suspected metastatic NSCLC","volume":"5","author":"Cheng","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/PO.20.00241","article-title":"Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer","volume":"5","author":"Palmero","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib41","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-19-0306","article-title":"Cell-free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer","volume":"26","author":"Pairawan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.011_bib42","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.annonc.2022.08.089","article-title":"Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)","volume":"33","author":"Bayle","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9076","article-title":"Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC)","volume":"41","author":"Rolfo","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.011_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221112696","article-title":"The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer","volume":"14","author":"Ezeife","year":"2022","journal-title":"Ther Adv Med Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:28:06Z","timestamp":1762550886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424025309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1556086424025309"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.011","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}